Refludan (lepirudin)
- Region
- 🇪🇺 EU
- Active substance
- lepirudin
- Company
- Celgene Europe Ltd.
- Status
- Withdrawn
- Therapeutic area
- Thromboembolism; Thrombocytopenia
- EU approval
- Thu 13 Mar 1997
- Application
- EMEA/H/C/000122
- ATC
- B01AE02
- Official record
- www.ema.europa.eu
Indication
Anticoagulation in adult patients with heparin-induced thrombocytopenia type II and thromboembolic disease mandating parenteral antithrombotic therapy. The diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.
Regulatory milestones
No milestones recorded in the last year.
Follow Refludan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.